Armen Asatryan

1.9k total citations
36 papers, 843 citations indexed

About

Armen Asatryan is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Armen Asatryan has authored 36 papers receiving a total of 843 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hepatology, 21 papers in Infectious Diseases and 16 papers in Epidemiology. Recurrent topics in Armen Asatryan's work include Hepatitis C virus research (30 papers), HIV/AIDS drug development and treatment (21 papers) and Systemic Lupus Erythematosus Research (11 papers). Armen Asatryan is often cited by papers focused on Hepatitis C virus research (30 papers), HIV/AIDS drug development and treatment (21 papers) and Systemic Lupus Erythematosus Research (11 papers). Armen Asatryan collaborates with scholars based in United States, France and New Zealand. Armen Asatryan's co-authors include Federico Mensa, Jens Kort, Teresa I. Ng, Ping Jiang, Mohamed‐Eslam F. Mohamed, Chih‐Wei Lin, Fred Poordad, Ahmed A. Othman, Robert J. Padley and Heidi S. Camp and has published in prestigious journals such as Gastroenterology, PLoS ONE and Hepatology.

In The Last Decade

Armen Asatryan

36 papers receiving 828 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Armen Asatryan United States	15	645	496	286	157	65	36	843
Prajakta Badri United States	15	658 1.0×	496 1.0×	250 0.9×	86 0.5×	98 1.5×	30	1.1k
Andrew J. Muir United States	14	1.2k 1.8×	998 2.0×	218 0.8×	139 0.9×	29 0.4×	35	1.4k
Joji Toyota Japan	18	1.5k 2.3×	1.2k 2.5×	371 1.3×	191 1.2×	80 1.2×	37	1.8k
Lisa M. Nyberg United States	16	1.5k 2.4×	1.4k 2.8×	241 0.8×	143 0.9×	41 0.6×	39	1.7k
Stephen Pianko Australia	19	862 1.3×	845 1.7×	92 0.3×	68 0.4×	43 0.7×	35	1.1k
Akshanth R. Polepally United States	16	412 0.6×	281 0.6×	202 0.7×	46 0.3×	171 2.6×	37	879
Nathalie Adda United States	18	2.0k 3.0×	1.8k 3.6×	685 2.4×	181 1.2×	66 1.0×	55	2.3k
Peggy Hwang United States	19	757 1.2×	654 1.3×	319 1.1×	49 0.3×	86 1.3×	59	1.1k
Carmen Mak United States	7	894 1.4×	752 1.5×	219 0.8×	52 0.3×	198 3.0×	11	1.2k
Elisabetta Degasperi Italy	19	887 1.4×	918 1.9×	90 0.3×	66 0.4×	32 0.5×	82	1.2k

Countries citing papers authored by Armen Asatryan

Since Specialization

Citations

This map shows the geographic impact of Armen Asatryan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Armen Asatryan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Armen Asatryan more than expected).

Fields of papers citing papers by Armen Asatryan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Armen Asatryan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Armen Asatryan. The network helps show where Armen Asatryan may publish in the future.

Co-authorship network of co-authors of Armen Asatryan

This figure shows the co-authorship network connecting the top 25 collaborators of Armen Asatryan. A scholar is included among the top collaborators of Armen Asatryan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Armen Asatryan. Armen Asatryan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Heo, Jeong, Yoon Jun Kim, Jin‐Woo Lee, et al.. (2021). Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials. Gut and Liver. 15(6). 895–903. 3 indexed citations

Poordad, Fred, Armen Asatryan, Humberto Aguilar, et al.. (2020). Long‐term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ‐I and TOPAZ‐II trials. Journal of Viral Hepatitis. 27(5). 497–504. 12 indexed citations

Foster, Graham R., Tarik Asselah, Lei Yang, et al.. (2019). Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS ONE. 14(1). e0208506–e0208506. 26 indexed citations

Gane, Edward, Fred Poordad, Neddie Zadeikis, et al.. (2019). Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease. Clinical Infectious Diseases. 69(10). 1657–1664. 23 indexed citations

Kosloski, Matthew P., Rajneet K. Oberoi, Stanley Wang, et al.. (2019). Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals. The Journal of Infectious Diseases. 221(2). 223–231. 14 indexed citations

Foster, Graham R., Gregory J. Dore, Stanley Wang, et al.. (2018). Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. Drug and Alcohol Dependence. 194. 487–494. 29 indexed citations

Poordad, Fred, Stanislas Pol, Armen Asatryan, et al.. (2017). Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure. Hepatology. 67(4). 1253–1260. 105 indexed citations

Lin, Chih‐Wei, et al.. (2017). Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers. European Journal of Drug Metabolism and Pharmacokinetics. 43(1). 81–90. 12 indexed citations

Gane, Edward, Fred Poordad, Joaquin Valdes, et al.. (2017). Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in Adults with Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. Gastroenterology. 152(5). S1089–S1089. 1 indexed citations

10.

Gane, E., F. Poordad, Joaquin Valdes, et al.. (2017). Pharmacokinetics and safety of glecaprevir/pibrentasvir in adults with chronic genotype 1–6 hepatitis C virus infection and compensated cirrhosis: an integrated analysis. Journal of Hepatology. 66(1). S306–S306. 3 indexed citations

11.

Poordad, Fred, Franco Felizarta, Armen Asatryan, et al.. (2017). Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment. Hepatology. 66(2). 389–397. 137 indexed citations

12.

Poordad, Fred, Stanislas Pol, Armen Asatryan, et al.. (2017). MAGELLAN-1, Part 2: Glecaprevir and Pibrentasvir for 12 or 16 Weeks in Patients with Chronic HCV Genotype 1 or 4 and Prior Direct-Acting Antiviral Treatment Failure. Gastroenterology. 152(5). S1057–S1057. 8 indexed citations

13.

Lin, Chih‐Wei, Sandeep Dutta, Tianli Wang, et al.. (2017). Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects. The Journal of Clinical Pharmacology. 57(12). 1616–1624. 13 indexed citations

14.

Gane, Edward, Fred Poordad, Stanley Wang, et al.. (2016). High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology. 151(4). 651–659.e1. 72 indexed citations

15.

Lin, Chih‐Wei, Sandeep Dutta, Armen Asatryan, et al.. (2016). Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of ABT-493: A First-In-Human Study. Journal of Pharmaceutical Sciences. 106(2). 645–651. 20 indexed citations

16.

Mohamed, Mohamed‐Eslam F., Heidi S. Camp, Ping Jiang, et al.. (2016). Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis. Clinical Pharmacokinetics. 55(12). 1547–1558. 101 indexed citations

17.

Poordad, Fred, Franco Felizarta, Stanley Wang, et al.. (2016). 752 High SVR Rates With the Combination of ABT-493 + ABT-530 for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 1 or 2 Infection. Gastroenterology. 150(4). S1046–S1047. 2 indexed citations

18.

Poordad, Fred, Stuart C. Gordon, Armen Asatryan, et al.. (2016). High Efficacy of Abt-493 and Abt-530 in Hcv Genotype 1 Infected Patients who Have Failed Direct-Acting Antiviral-Containing Regimens: The Magellan-I Study. Journal of Hepatology. 64(2). S160–S161. 16 indexed citations

19.

Foster, Graham R., Edward Gane, Armen Asatryan, et al.. (2016). Endurance-3: A Phase 3, Randomized, Open-Label, Active-Controlled Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with HCV Genotype 3 Infection. Journal of Hepatology. 64(2). S292–S292. 2 indexed citations

20.

Lawitz, Eric, William O’Riordan, Armen Asatryan, et al.. (2015). Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection. Antimicrobial Agents and Chemotherapy. 60(3). 1546–1555. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact